Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Secretory antibody" patented technology

Secretory antibodies are typically produced at mucosal surfaces and transported through epithelial cells for secretion at the luminal site. Importantly, secretory antibodies comprise both IgM and IgA, and both isotypes can harbour a J-chain that binds to the polymeric Ig receptor (pIgR).

CD19 targeted chimeric antigen receptor, method of dual-modifying same, and application of the CD19 targeted chimeric antigen receptor

The invention relates to a CD19 targeted chimeric antigen receptor and an application thereof, and particularly provides a polynucleotide sequence, which is selected from: (1) a polynucleotide sequence which contains, in a successively connected manner, an encoding sequence of anti-CD19 single-chain antibody, an encoding sequence of human CD8[alpha] hinge zone, an encoding sequence of human CD28 transmembrane zone, an encoding sequence of human CD28 intracellular zone, an encoding sequence of human CD3 [zeta] intracellular zone, and optionally, a fraction, which contains an extracellular domain III and an extracellular domain IV of EGFR, and an encoding sequence of anti-human PD1 sequence fraction; and (2) a complementary sequence of the polynucleotide sequence (1). The invention also provides related fusion proteins, a carrier containing the encoding sequences, and applications of the fusion proteins, encoding sequences and carrier. The CAR-T cell has strong killing effect on specifictumor cells, and can reach more than 90% in killing efficiency on the specific tumor cells under the multiplicity of infection of 1:2. The CAR-T cell can secrete the PD1 antibody and has regulation effect on immunosuppression micro-environments.
Owner:HRAIN BIOTECHNOLOGY CO LTD

Construction and application of chimeric antigen receptor-T (CAR-T) cells capable of targeting mesothelin and carrying PD-L1 blocking agent

The invention relates to the field of tumor immunology, in particular to construction and application of chimeric antigen receptor-T (CAR-T) cells capable of targeting mesothelin and carrying a PD-L1blocking agent. The CAR-T cells are constructed by transfecting a CAR capable of targeting the mesothelin and carrying the PD-L1 blocking agent, wherein the CAR capable of targeting the mesothelin andcarrying the PD-L1 blocking agent is formed by a leader peptide of a CD8 antigen, an anti-mesothelin single-chain antibody, a hinge region, a transmembrane region, an intracellular signal domain andan anti-PD-L1 antibody secretion region which are sequentially connected with one another. The mesothelin SS1P scFv of the CAR-T cells provided by the invention can specifically bind to tumor cells expressing mesothelin glycoprotein and promote the secretion of anti-tumor-related cytokines, thereby achieving a killing effect on the tumor cells; furthermore, the CAR-T cells provided by invention can also secrete a PD-L1 antibody, specifically bind to PD-L1 produced by tumor cell expression, and block the inhibitory effect of a PD-L1/PD-1 signal on T cell activity, thus facilitating the long-term effective inhibition of the CAR-T on tumor cell growth.
Owner:SUZHOU MAXIMUM BIO TECH CO LTD

Preparation method of alpha-glucan antigen and specificity monoclonal antibody

The invention discloses a preparation method of an alpha-glucan antigen and a specificity monoclonal antibody. The preparation method of the antigen comprises the following steps: mixing alpha-glucan and protein; dissolving with water; regulating the pH of solution to 5-8; carrying out freeze drying, and grinding into powder; putting the powder in the environment with constant temperature of 50-60DEG C and relative humidity of 60-90%; reacting for at least three days to obtain the alpha-glucan antigen. The preparation method of the antibody comprises the following steps: mixing the prepared antigen with an adjuvant, emulsifying the mixture, and injecting the emulsified mixture into animal bodies; blending the splenocyte and oncocyte of the animal body with the high serum valence to obtain a hybridoma cell capable of secreting the antibody; and producing the antibody by the hybridoma cell or with an ascites method. The antibody prepared by the method has high immunogenicity, and can be used for effectively inducing to generate immune response to obtain the antibody with the excellent property. The antibody obtained by the method provided by the invention can be subjected to specificity reaction with the alpha-glucan to generate macroscopic precipitates, and the antibody has high valence and can be used for the quantitative analysis on the alpha-glucan.
Owner:GUANGZHOU SUGARCANE IND RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products